SCHEMBL19407086

SCHEMBL19407086

CO[C@H]1CC[C@@H](CC(C)C)CC1

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.34
▸ TDO2 P48775 1/20 0.34
▸ DAO P14920 1/20 0.33
▸ KCNQ3 O43525 1/20 0.31
▸ KCNQ2 O43526 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13910184 1.00 IDO1 (0.34) IDO1TDO2DAOKCNQ3KCNQ2
SCHEMBL178340 1.00 IDO1 (0.34) IDO1TDO2DAOKCNQ3KCNQ2
SCHEMBL2461 0.82 — —
SCHEMBL21775731 0.82 OPRK1 (0.34) —
SCHEMBL21297615 0.80 IDO1 (0.32) IDO1TDO2DAO
SCHEMBL25143837 0.79 — —
SCHEMBL19407066 0.79 — —
SCHEMBL19407073 0.79 — —
SCHEMBL25962346 0.79 — —
SCHEMBL102231 0.79 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. (US) 2023-11-09 — — US disclosed
US-11685732-B2 MYST family histone acetyltransferase inhibitors Epizyme, Inc. (US) 2023-06-27 — — US disclosed
US-20220162197-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. 2022-05-26 — — US disclosed
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 — — US disclosed
US-20170273985-A1 TRICYCLIC DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162197-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS EP300, KAT2A, KAT6A IDO1 3115/4885TDO2 4547/4885DAO 4286/4885
US-20170273985-A1 TRICYCLIC DERIVATIVE PDE3A, PDE2A, PDE5A IDO1 1649/4885TDO2 1686/4885DAO 781/4885
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE PDE3A, PDE2A, PDE5A IDO1 572/4885TDO2 2314/4885DAO 312/4885
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS EP300, KAT2A, KAT6A IDO1 3115/4885TDO2 4547/4885DAO 4286/4885
US-11685732-B2 MYST family histone acetyltransferase inhibitors EP300, KAT2A, KAT6A IDO1 3115/4885TDO2 4547/4885DAO 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback